



# Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013–2021)

ORIGINAL RESEARCH

FRANCESCO DI GENNARO 

ROSSANA LATTANZIO

GIACOMO GUIDO

AURELIA RICCIARDI

ROBERTA NOVARA

GIULIA PATTI

SERGIO COTUGNO

ELDA DE VITA

GAETANO BRINDICCI

MICHELE FABIANO MARIANI

LUIGI RONGA

CARMEN RITA SANTORO

FEDERICA ROMANELLI

STEFANIA STOLFA

ROBERTA PAPAGNI

DAVIDE FIORE BAVARO

GIUSI DE IACO

ANNALISA SARACINO

\*Author affiliations can be found in the back matter of this article

Ubiquity press

## ABSTRACT

**Background:** The COVID-19 pandemic has undone years of progress in providing essential TB services and controlling the TB burden. Italy, a low TB burden country, has an incidence of 7.1 cases per 100,000 people. To control the TB spreading in Italy is critical to investigate the characteristics of patients with the worst outcomes and the highest risk of adverse events related to antituberculosis therapy. Therefore, we conducted a large retrospective study in TB patients admitted to the Clinic of Infectious Diseases University of Bari, Italy, in order to describe the clinical presentation and the factors associated with adverse events and outcomes.

**Methods:** We retrospectively evaluated the patients admitted to the Clinic of Infectious Diseases from January 2013 to 15 December 2021. We stratified our cohort into two groups: <65 years of age and ≥65 years in order to assess any differences between the two groups. Two logistic regression models were implemented considering the dependent variables as: (I) the adverse events; and (II) the unsuccessful treatments.

**Results:** In total, 206 consecutive patients [60% (n = 124) M, median age 39 years, range 16–92] were diagnosed and admitted with TB at Clinic of Infectious Diseases. Of the whole sample, 151 (74%) were <65 years and 55 (26%) were ≥65. Statistically significant differences between the two groups were detected (*p*-value < 0.05) for nationality (*p*-value = 0.01), previous contact with TB patient (*p*-value = 0.00), type of TB (*p*-value = 0.00), unsuccessful treatment (*p*-value = 0.00), length of hospitalization (*p*-value = 0.02) and

CORRESPONDING AUTHOR:

**Francesco Di Gennaro, MD**

Clinic of Infectious Diseases,  
University of Bari “Aldo Moro”,  
Department of Biomedical  
Sciences and Human Oncology,  
Bari, IT

[Francesco.digennaro1@uniba.it](mailto:Francesco.digennaro1@uniba.it)

Di Gennaro F, Lattanzio R, Guido G, Ricciardi A, Novara R, Patti G, Cotugno S, De Vita E, Brindicci G, Mariano MF, Ronga L, Santoro CR, Romanelli F, Stolfa S, Papagni R, Bavaro DF, De Iaco G, Saracino A. Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013–2021). *Annals of Global Health*. 2022; 88(1): 26, 1–12. DOI: <https://doi.org/10.5334/aogh.3677>

diagnostic delay ( $p$ -value = 0.01). Adverse events related to TB drug regimen were reported in 24% ( $n = 49$ ). Age < 65 years (O.R. = 3.91; 95% CI 1.72–4.21), non-Italian nationality (O.R. = 4.45; 95% CI 2.22–4.98.), homeless (O.R. = 3.23; 95% CI 2.58–4.54), presence of respiratory symptoms (O.R. = 1.23; 95% CI 1.10–1.90), diagnostic delay (O.R. = 2.55; 95% CI 1.98–3.77) resulted associated with unsuccessful treatment outcome (death, failure or lost to follow up). Finally, age < 65 years (O.R. = 1.73; 95% CI 1.31–2.49), presence of pulmonary TB (O.R. = 1.15; 95% CI 1.02–1.35), length of hospitalization (O.R. = 1.82; 95% CI 1.35–2.57) and TB culture positive (O.R. = 1.35; 95% CI 1.12–1.82) were associated with adverse events in our populations.

**Conclusions:** The pharmacological approach alone seems insufficient to treat and cure a disease whose ethiopathogenesis is not only due to the *Mycobacterium tuberculosis*, but also to the poverty or the social fragility. Our data suggest that young foreigners, the homeless, and the people with low social and economic status are at higher risk of an unfavorable outcome in low incidence TB countries. Targeted actions to support this highly vulnerable population both in terms of outcome and occurrence of adverse events are needed.

## BACKGROUND

Tuberculosis (TB) is still one of the world's leading killers and one of the most serious public health issues, with 10 million new cases diagnosed each year and 1.5 million deaths [1]. Thirty high TB burden countries, the majority of which are in Sub-Saharan Africa, account for nearly 90% of all TB cases each year [2]. Unfortunately, the COVID-19 pandemic has undone years of progress in providing essential TB services and controlling the TB burden [3, 4]. In fact, a significant drop in new TB diagnoses, down 18% from 7.1 million in 2019 to 5.8 million in 2020, was observed, bringing this score back to around ten years ago [1, 2]. Furthermore, there has also been a 15% decrease in access to TB care, an increase in diagnostic delay and worse outcomes. These indicators are also expected to deteriorate further until 2022, effectively undoing the previous decade's significant efforts and commitments to combat TB [1, 2]. In most of the 30 high TB burden countries, TB notification rate is around 150–400 cases per 100 000 population [4]. In low endemic countries such as Italy, TB mainly affects vulnerable populations such as immigrants, homeless, gypsies, prisoners and elderly ( $\geq 65$  years old) [5]. Italy, a low TB burden country, has an incidence of 7.1 cases per 100 000 people. Moreover, approximately 60% of cases are due to the migrant population coming from areas of high TB incidence (such as Africa, Asia and Eastern Europe). The most foreigners come from African countries (Senegal, Ghana, Nigeria, Cameroon), Eastern Europe (Albania, Bulgaria, Ukraine, and Poland), and the Indian subcontinent (India, Bangladesh, and Pakistan), where the epidemiological situation is complicated by the spread of multi drug resistant (MDR) or extensively drug-resistant (XDR) strains [6, 7]. Furthermore, the impact of the COVID-19 pandemic on TB services is estimated as dramatic, particularly in countries where TB-related healthcare personnel have been allocated to the COVID-19 emergency. The WHO warned that the COVID-19 pandemic's interruption of TB services might result in fewer TB diagnosis, longer diagnostic delays, and increase of the TB mortality and the onset TB MDR [1]. For this reason, it is critical to investigate the characteristics of patients with the worst outcomes and the highest risk of adverse events related to antituberculosis therapy with the aim to effectively control TB spreading in Italy.

Therefore, we conducted a large retrospective study by evaluating patients with pulmonary TB admitted to the University Clinic of Infectious Diseases, University of Bari, Apulia region, south of Italy in order to describe the clinical presentation and the factors associated with adverse events and outcomes.

## MATERIALS AND METHODS

### STUDY DESIGN AND PATIENTS

We performed a retrospective study in patients diagnosed with pulmonary TB admitted to the University Clinic of Infectious Diseases University of Bari, Bari, Italy, from 1 January 2013 to 15 December 2021. We retrospectively evaluated data from each patient admitted in our hospital

with pulmonary active TB. According to the WHO guidelines, enrolled patients were classified as “active pulmonary TB” if the diagnosis was based: (1) on a positive culture for *M. tuberculosis* from a respiratory sample (sputum or bronchoalveolar lavage) or other biological specimens; (2) on positive *M. tuberculosis* nucleic amplification test NAT (Xpert® MTB/RIF, Cepheid, USA) from biological specimens (without culture confirmation); or (3) on histopathological findings consistent with TB and presence of acid fast bacilli (AFB) in a tissue sample. Moreover, patients were classified as “clinical TB” if the diagnosis was based on clinical and radiologic criteria (having excluded other diseases) including appropriate response to standard anti-TB therapy.

Patients were treated according to the institutional protocol drawn up following the WHO TB guidelines [8]. The first week of treatment was spent in the hospital until AFB sputum conversion was accomplished on three consecutive negative samples taken over the course of a week. During their stay in the hospital, patients received direct observed therapy. Patients were subsequently followed monthly on ambulatory care by certified TB experts after discharge for the duration of their treatment. Until the treatment was finished, laboratory tests were performed almost weekly, or as needed depending on the clinical status. Medical advice was provided about the likelihood of adverse drug events and the need of reporting any adverse event to their doctor as soon as possible. Patients were also provided a booklet with information on the most prevalent anti-TB drugs adverse effects.

## DATA COLLECTION

Patient demographics; admission and discharge/death dates; and clinical variables: symptoms, tuberculosis diagnosis, *M. tuberculosis* drug resistance, TB location, treatment regimen, adverse events (type, severity, management), and outcomes were the key data sources. The severity of adverse events was defined as light (asymptomatic laboratory findings only; modest signs/symptoms; no medical intervention necessary), moderate (necessitating limited non-invasive intervention), and severe (significant symptoms requiring hospitalization) [9].

## STATISTICAL ANALYSIS

No formal sample size was calculated *a priori*, since the study included all patients admitted during the study period. Continuous data were expressed as median and interquartile range (IQR), and categorical data as numbers and percentages. Chi-squared test or Fisher’s exact test as appropriate were used to compare categorical variables. We stratified our cohort into two groups: <65 years of age and ≥65 years in order to evaluate any differences between these two groups.

Two logistic regression models were implemented considering the dependent variables as: (1) the adverse events; and (2) unsuccessfully treated (died, lost to follow up and failed patients) while each of the available factors were considered as independent variables (univariate analysis). All the factors with a *p-value* < 0.10 at the univariate analyses were included in the models. Multicollinearity among covariates was assessed through the variance inflation factor (VIF), taking a value of two for excluding a covariate. However, no variable was excluded according to the previous criterion.

Odds ratios (ORs) as adjusted odds ratios (Adj-ORs) with their 95% confidence intervals (CIs) were used to measure the association between factors at the baseline (exposure) and treatment failure (outcome).

All two-tailed test *p value* less than 0.05 were considered statistically significant. Statistical analysis was performed using STATA V.13.

## RESULTS

Between January, 1 2013 and December, 15 2021, 206 consecutive patients [60% (n = 124) M, median age 39 years, range 16–92] were diagnosed and admitted with TB at the Clinic of Infectious Diseases, and included in the study. Of the whole sample, 151 (74%) were <65 years. Median age was 32 years (16–63) and 71 years (65–92) for <65 years group and ≥65 years one,

respectively. Among them, 51% (n = 105) had non-Italian nationality, 8% (n = 17) were homeless, and 65% (n = 135) had a pulmonary localization of TB. Notably, 60% (n = 124) had respiratory symptoms. Furthermore, 68% (n = 140) were culture positive and 16% (n = 34) showed at least one drug resistance. Fifty-seven percent (n = 117) successfully completed the treatment, while 1% (n = 4) died due to a TB-related cause. At the time of the study, treatment was still ongoing 10% (n = 20) of the sample. Furthermore, the treatment success rate in ≥65 years group was 84% (n = 46), while in <65 years was 45% (n = 71).

**Table 1** shows the characteristics of all participants on the whole sample and stratified by age-classes <65 or ≥65 years old. Differences in distribution of the variables collected between <65 or ≥65-year-old groups emerged (*p-value* < 0.05) for nationality (*p-value* = 0.01), previous contact with TB patient (*p-value* = 0.00), type of TB (*p-value* = 0.00), unsuccessful treatment (*p-value* = 0.00), length of hospitalization (*p-value* = 0.02) and diagnostic delay (*p-value* = 0.01) as shown in **Table 1**.

**Table 1** Characteristics of participants stratified by age-classes <65 or ≥65 years old.

		ADMITTED PATIENTS			P-VALUE
		TOTAL N. 206 (100%)	AGED < 65 N. 151 (100%)	AGED ≥ 65 N. 55 (100%)	
Sex	M	124 (60)	91 (74)	33 (26)	0.9
	F	82 (40)	60 (75)	22 (25)	
	Age Median (IQR)	39 (16–92)	32 (16 – 63)	71 (65 -92)	0.00
Nationality	Italian	101 (49)	54 (53)	47 (47)	0.01
	Non-Italian	105 (51)	97 (94)	8 (6)	
	Homeless	17 (8)	17 (100)	0 (0)	NA
	HIV + status	6 (3)	5 (84)	1 (16)	0.9
	Previous contact with tb patient	60 (30)	52 (88)	8 (12)	0.00
	Hospital stay, median	44,5	43 (7–230)	24 (4–45)	0.02
	Diagnostic delay, median	76	127 (2–450)	43 (5–120)	0.01
Type	Pulmonary TB	135 (65)	107 (80)	28 (20)	0.00
	Extrapulmonary TB	64 (31)	38 (60)	26 (40)	0.01
	Miliary TB	7 (4)	6 (86)	1 (14)	0.7
	Respiratory symptoms	124 (60)	101 (81)	25 (19)	0.02
Type of diagnosis	Culture positive	140 (68)	107 (77)	33 (23)	0.03
	Radiological	42 (20)	31 (74)	11 (26)	0.03
	NAT	5 (2)	2 (40)	3 (60)	0.2
	Histological	19 (9)	10 (48)	9 (52)	1
	IGRA test	123 (62)	97 (78)	26 (22)	0.08
Initial Therapeutic Scheme, n (%)	R+H+E+Z	166 (80)	123 (75)	44 (25)	0.9
	Drug regimen without Z Including Amikacin	5 (2)	2 (40)	3 (60)	0.6
	Drug without Z regimen including fluoroquinolone	1 (1)	1(100)	0 (0)	NA
Resistance Pattern	Monoresistance	34 (16)	25 (73)	9 (27)	0.3
	H	18 (9)	14 (77)	4 (23)	0.7
	R	13 (6)	7 (54)	5 (46)	0.5
	Z	3 (1)	2 (66)	1 (34)	1
	MDR	9 (4)	9 (100)	0 (0)	0.1
Adverse events and management, n (%)	Adverse events	49 (25)	36 (73)	13 (27)	0.3
	Therapeutic Shift	24 (12)	19 (80)	6 (20)	0.5
Outcomes	Exitus	4 (1)	3 (75)	1 (25)	0.8
	Successful treatment	117 (57)	71 (60)	46 (40)	0.1
	Unsuccessful treatment	65 (32)	61 (94)	4 (6)	0.00
	Treatment on going	20 (10)	16 (66)	4 (34)	0.1

Adverse events related to the TB drug regimen were reported in 24% (n = 49) of patients. Out of the 49 patients who reported an adverse event, 55% (n = 27) showed a liver disease. In 51% (n = 25) of the 49 patients, the event required minimal non-invasive intervention classified as mild while 49% (n = 24) of cases required a suspension of the suspect drug and change of the treatment. Further characteristics of adverse events reported in the sample are shown in [Table 2](#).

	CHARACTERISTICS	TOTAL N. 49 (100%)
<b>Type of Adverse events, n (%)</b>	Hepatitis	27 (55)
	Neurological	5 (11)
	Ocular damage/decrease in visual acuity	5 (11)
	Itching/skin rash	11 (22)
	Acute renal failure	1 (1)
<b>Severity of Adverse events, n (%)</b>	Mild	25 (51)
	Moderate	18 (37)
	Severe	6 (22)
<b>Adverse events management, n (%)</b>	Therapeutic shift	24 (49)
	Temporary suspension of all treatment	9 (18)
	Support therapy and no change of treatment	16 (33)

**Table 2** Characteristics of adverse events in the 49 patients who reported them.

The multivariate logistic model on unsuccessful outcome considered the effects of age, gender, nationality, homelessness, presence of respiratory symptoms, diagnostic delay, length of hospitalization, acid-fast bacilli smear positive, drug resistance, treatment, TB localization (lung or extrapulmonary) and TB culture positivity. Significant predictors of unsuccessful outcome are reported in [Table 3](#). Age < 65 years (O.R. = 3.91; 95% CI 1.72–4.21), non-Italian nationality (O.R. = 4.45; 95% CI 2.22–4.98.), homelessness (O.R. = 3.23; 95% CI 2.58–4.54), presence of respiratory symptoms (O.R. = 1.23; 95% CI 1.10–1.90), diagnostic delay (O.R. = 2.55; 95% CI 1.98–3.77) resulted associated with unsuccessful treatment outcome (death, failure or lost to follow up), as reported in [Table 3](#).

CHARACTERISTICS	UNIVARIATE ANALYSIS O.R.	MULTIVARIATE ANALYSIS ADJ-O.R.
Age < 65	1.22 (0.98–1.64)	3.91 (1.72–4.21)*
Female	0.48 (0.16–0.90)	0.68 (0.16–1.10)
Non-Italian nationality	1.40 (1.28–1.76)	4.45 (2.22–4.98)*
Homeless	1.51 (1.28–2.03)	3.23 (2.58–4.54)*
Diagnostic delay	1.72 (1.08–2.01)	2.55 (1.98–3.77)*
Length of hospitalisation	1.15 (0.68–1.54)	1.42 (0.85–1.87)
Pulmonary TB	1.21 (0.28–1.23)	1.13 (0.88–1.94)
Extrapulmonary TB	1.14 (0.88–1.58)	1.84 (0.91–2.78)
Respiratory symptoms	1.26 (0.85–1.72)	1.23 (1.10–1.90)*
Culture positive	1.64 (0.38–1.78)	1.24 (0.38–1.48)
Mono-resistance, n	0.35 (0.12–0.60)	0.75 (0.45–1.34)
MDR	1.21 (0.89–1.73)	–
R + H + E + Z	0.79 (0.68–1.21)	1.10 (0.83–2.21)
Drug regimen without Z including Amikacin	0.59 (0.48–1.21)	–

**Table 3** Predictors of unsuccessful treatment for active pulmonary tuberculosis.

**Legend**

R: Rifampicin  
H: Isoniazid  
E: Ethambutol  
Z: Piralidine  
TB: Tuberculosis.

The multivariate logistic model on the adverse events considered the effects of age, gender, nationality, homelessness, presence of respiratory symptoms, diagnostic delay and length of hospitalization, acid-fast bacilli smear positive, drug resistance, treatment and TB culture positivity, TB localization (lung or extrapulmonary). Age < 65 years (O.R. = 1.73; 95% CI 1.31–2.49), presence of pulmonary TB (O.R. = 1.15; 95% CI 1.02–1.35), length of hospitalization (O.R. = 1.82; 95% CI 1.35–2.57) and TB culture positive (O.R. = 1.35; 95% CI 1.12–1.82) resulted associated with adverse events in our populations, as reported in [Table 4](#).


CHARACTERISTICS	UNIVARIATE ANALYSIS O.R.	MULTIVARIATE ANALYSIS ADJ-O.R.
Age <65	1.18 (0.81–3.47)	1.73 (1.31–2.49)*
Female	0.48 (0.26–1.09)	0.38 (0.16–1.05)
Non-Italian nationality	1.40 (0.88–1.76)	0.95 (0.82–1.59)
Homeless	0.75 (0.55–1.06)	0.88 (0.55–1.18)
HIV status	0.44 (0.28–1.06)	–
Diagnostic delay	1.10 (0.68–1.41)	1.45 (0.75–1.97)
Length of hospitalisation	1.25 (0.88–1.71)	1.82 (1.35–2.57)*
Pulmonary TB	0.76 (0.38–1.08)	1.15 (1.02–1.35)*
Extrapulmonary TB	0.70 (0.48–1.16)	0.83 (0.62–1.16)
Respiratory symptoms	1.21 (0.88–1.76)	0.95 (0.82–1.58)
Culture positive	1.20 (0.78–1.56)	1.35 (1.12–1.82)*
Monoresistance, n	0.64 (0.48–0.96)	0.95 (0.82–1.29)
MDR	1.40 (0.88–1.76)	–
R + H + E + Z	1.04 (0.88–1.46)	0.85 (0.72–1.64)
Drug regimen without Z including Amikacin	0.39 (0.28–0.56)	–

**Table 4** Predictors of adverse events for active pulmonary tuberculosis.

**Legend**

- R: Rifampicin
- H: Isoniazid
- E: Ethambutol
- Z: Piralidine
- TB: Tuberculosis.

Furthermore, [Figure 1](#) shows the temporal trend (2013–2021) of admitted TB patients and lost one to follow-up.



**Figure 1** 2013–2021 trend of admitted patients and lost to follow up.

**DISCUSSION**

Our study describes a cohort of patients admitted in a referral hospital for TB in Italy referred to a large time period (2013–2021). According to the WHO definitions, 140 out of 206 patients were microbiologically confirmed with pulmonary TB. A global successful treatment was reported in half of our sample, while one out four reported an adverse event related to TB drug regimen and 16% presented at least of one drug resistance. Stratifying our data by age classes <65 or ≥65 years old, differences were found in: nationality, previous contact with TB, length of hospitalization, diagnostic delay.



Quite surprising are the results concerning the factors associated with an unsuccessful outcome. In fact, in our sample, age < 65 years, non-Italian nationality, homelessness, presence of respiratory symptoms, and a diagnostic delay resulted associated with an unsuccessful treatment outcome (death, failure or lost to follow up).

In line with European data, in our cohort there is a slight prevalence of male subjects [10, 11] and almost three-quarters of our cohort belonged to the younger group with a median age of 39 years; our study population is younger than would be expected in low TB burden countries in which the geriatric population represents a large reservoir of TB infection [12, 13].

This result is due to the fact that 51% of our patients were foreigners and 94% of them were less than 65 years. In our case, the role of the migrant population is greater than in the rest of Europe. In fact, the latest 2021 report records that approximately one third (34.5%) of TB cases reported in the EU/EEA in 2019 were of foreign origin [10, 14].

Several authors showed as being elderly is a risk factor for a worse outcome and expose to a major risk of adverse events [15, 16]. This contradiction with our data may be explained on the one hand by the good therapeutic and follow-up management towards this risk category and on the other hand may have been influenced by the fact that highly vulnerable populations such as migrants, homeless and foreigners were under 65 years of age [13, 17]. In fact, as showed by several experiences, foreigners, homelessness and more generally a low socio-economic level impact in worsening outcomes [18]. In fact, a recent meta-analysis of more than 400 000 patients shows that the risk of MDR is at least twice as high in populations with a lower socio-economic level [19].

In EU countries, the average treatment success rate for active TB has been reported as 60%–87%. Our data globally showed a 57% of successful treatment, but with a notably difference between the two groups [10]. In fact, success treatment rate in ≥65-year-old group was 84% (n = 46), while in <65-year-olds it was 45% (n = 71). These underlines how we are fully above the European average for the elderly TB population while our data represent below average for the <65 years group representing the great vulnerability and fragility of this population for the greater presence in this group of migrants, homeless people with known social fragilities which are then reflected in health outcomes [20, 21].

Moreover, Apulia and the other regions of South Italy are located in the middle of the Mediterranean migration route with high prevalence of migrant population that represents a pivotal key to TB burden control [22].

Furthermore, in our cohort one out four patients showed an adverse event related to TB drug regimen. Around half of them showed a hepatitis and half of these patients changed treatment. Factors associated with adverse events were age < 65 years, pulmonary TBC, length of hospitalization and TB culture positive.

This is in contradiction with the literature which shows a variable percentage of 15–75% of adverse events in the over 65 and especially over 75 population [23, 24]. This could be explained by careful therapeutic and clinical management for the elderly, in a multidisciplinary approach with specialists for the other comorbidities of these patients, and in a close up clinical and hematochemical followed up [25]. Regardless drugs, pyrazinamide was responsible for the majority of adverse reactions as showed in literature, but unfortunately we do not have data on drugs due to toxicity [26, 27].

Furthermore, our data show that patients under 65 have a higher diagnostic delay than patients over 65 (76 days vs. 43 days) and also higher hospital length of stay (43 vs. 24). Our study found a median TD of 76 days in line with other regions of our country (77.5 days in Lazio, greater instead than Emilia Romagna with a TD of 65 days) [28]. This finding is also in agreement with the TD estimated in a review conducted on 58 studies, performed in both low- and high-endemic countries, which reported a delay within the range of 60 to 90 days [29].

There may be several reasons for what has been observed: in a country with low endemicity for tuberculosis there is a low awareness of the disease both by the patients and by the general practitioners; in our case series, the extra-pulmonary forms, which are characterized by a more specific symptomatology and do not present the classic clinical pattern of the respiratory forms,

are more frequent in the young population. Moreover, a large part of the young population is represented by migrants who, despite the presence in our country of a free national health system, may experience difficulties due to the condition of irregular migrants without access to the general practitioners and because of this the diagnosis is often only made after the access to the public hospitals due to the manifestations of the advanced clinical forms.

Another statistically significant difference between the young and elderly population was found in the length of stay. In the younger the average length of stay is 43 days (with a wide range from 7 to 230 days) versus 24 days in the older population (from 5 to 120 days). As already observed in other studies, the risk of hospitalization is not only influenced by clinical factors, but also by social determinants and high hospitalization times is generally greater in: migrants who have been in the country of arrival for more than two years, the homeless and patients with multidrug-resistant TB [30, 31]. However, some studies conducted in countries with low TB incidence reported that more than three quarters of patients are initially treated as inpatients and in many cases this is an unreasonable choice with longer hospitalization times than strictly necessary. This result is in line with the study of Aslam et al., which estimated that about 38% of hospitalizations were avoidable [32].

Furthermore, [Figure 1](#) also allows for two reflections. The first is the reduction in TB diagnoses during the SARS CoV2 pandemic, as well as the lockdown periods with interruption and disruption of TB services due to the pandemic's need and workload. As several authors have reported, this may have a negative impact on Tb burden control, with an increase in clinical severity, diagnostic delay, and, more broadly, a reduction in TB control, pushing the results obtained in the fight against tuberculosis back ten years.

The second reflection is on the potential impact of establishing a tuberculosis-specific medical and nursing team for those who were lost to follow-up. In fact, as of 2019, a team specializing in tuberculosis is caring for patients in our hospital, which could explain the significant decrease in lost to follow-up over the last three years. Of course, studies focusing on this potential impact are required to demonstrate the intervention's potential effectiveness.

We acknowledge that our study has some limitations. First, the inclusion of the patients diagnosed at a single institution may limit the generalizability of the results. Moreover, due to the study's retrospective nature, other factors potentially influencing outcomes, such as lack of comorbidity data, radiological findings, and other risk factors, were not considered. Furthermore, in our study, we only considered total diagnostic delay, with no distinction made between healthcare system and patient delays.

## CONCLUSION

In conclusion, our data suggest that young foreigners, the homeless, and people with low social and economic status are at higher risk of an unfavorable outcome in low incidence TB countries. According to the WHO, one of the pilot keys for high-income countries to control TB burden is to target TB vulnerable groups [33–36]. Targeted actions to support this highly vulnerable population both in terms of outcome and occurrence of adverse events are needed. The pharmacological approach alone seems insufficient to treat and cure a disease whose etiopathogenesis is not only related to *the Mycobacterium Tuberculosis*, but also to the poverty. The establishment of a dedicated medical and nursing team for tuberculosis could improve outcomes and reduce lost to follow-up for this vulnerable population, but more integrated social actions are required. Hospitalization in tertiary referral hospitals with clinical multidisciplinary expertise in TB diagnosis and treatment can be useful to improve outcome in the elderly. Concentrating elderly TB patients to referral facilities is important to ensure a better outcome for this fragile population, which is different from the previous one and requires dedicated expertise on TB care.

Furthermore, new treatments and short regimens should be specifically evaluated in vulnerable populations to increase adherence, reduce the risk to lost to follow up, reduce the pill burden and treatment time, and improve outcome and safety. Future research is therefore needed to evaluate targeted interventions to assist vulnerable populations and to effectively control and eliminate tuberculosis as a goal of sustainable development.



## DATA ACCESSIBILITY STATEMENT

All authors confirm that the data supporting the findings of this study are available within the article. All datasets generated and/or analyzed during the current study are available from the corresponding author on request. Data request can be made through the corresponding author's email.

## ABBREVIATIONS

TB: Tuberculosis

WHO: World Health Organization

EU: European Countries

MDR: multi drug resistant

XDR: extensively drug-resistant

R: Rifampicin

H: Isoniazid

E: Ethambutol

Z: Piraldine

M.t: Mycobacterium tuberculosis

PD: patient delay

HD: hospital delay

DD: diagnostic delay

TD: total delay

## ETHICS AND CONSENT

The study was conducted in accordance to the regulations and guidelines of the University of Bari Italy. The rights of all participants were protected, the confidentiality of the data was maintained to ensure the safety and privacy of all participants. Prior to the study, school meetings were held during which the purpose and procedures of the study were discussed. Informed consent was obtained from all subjects and/or their legal guardian(s). Ethical approval was provided by the Ethics and Protocol Review of University of Bari (CE130121).

## ACKNOWLEDGEMENTS

All the patients with TB, they give us the sense of life.

## COMPETING INTERESTS

The authors have no competing interests to declare.

## AUTHOR CONTRIBUTIONS

Conceptualization: F.D.G. and R.L.; methodology: D. F. B, C.R.S, G.B. and L.R.; writing—original draft preparation: R.P., R.N. A.R. G.G., S.C., G.P., S.S., F.R.; writing—review and editing: A.S., M.M., G.D, F. D. G.; supervision: A.S. and F.D.G. All authors have read and agreed to the published version of the manuscript.

## AUTHOR AFFILIATIONS

**Francesco Di Gennaro**  [orcid.org/0000-0003-3453-5647](https://orcid.org/0000-0003-3453-5647)

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Rossana Lattanzio**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Giacomo Guido**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Aurelia Ricciardi**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Roberta Novara**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Giulia Patti**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Sergio Cotugno**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Elda De Vita**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Gaetano Brindicci**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Michele Fabiano Mariani**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Luigi Ronga**

Microbiology and Virology Unit, University of Bari, University Hospital Policlinico, Bari, IT

**Carmen Rita Santoro**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Federica Romanelli**

Microbiology and Virology Unit, University of Bari, University Hospital Policlinico, Bari, IT

**Stefania Stolfi**

Microbiology and Virology Unit, University of Bari, University Hospital Policlinico, Bari, IT

**Roberta Papagni**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Davide Fiore Bavaro**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Giusi De Iaco**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

**Annalisa Saracino**

Clinic of Infectious Diseases, University of Bari “Aldo Moro”, Department of Biomedical Sciences and Human Oncology, Bari, IT

1. **World Health Organization (WHO).** *Global Tuberculosis Report 2021*. Geneva: WHO; 2021. <https://www.who.int/publications/i/item/9789240037021>
2. **Chakaya J, Khan M, Ntoui F,** et al. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts. *Int J Infect Dis.* 2021 Mar 11; S1201–9712(21); 00193–4. DOI: <https://doi.org/10.1016/j.ijid.2021.02.107>
3. **Togun T, Kampmann B, Stoker NG, Lipman M.** Anticipating the impact of the COVID-19 pandemic on TB patients and TB control programmes. *Ann Clin Microbiol Antimicrob.* 2020 May 23; 19(1): 21. DOI: <https://doi.org/10.1186/s12941-020-00363-1>
4. **Di Gennaro F, Gualano G, Timelli L,** et al. Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital. *Antibiotics (Basel).* 2021 Mar 8; 10(3): 272. DOI: <https://doi.org/10.3390/antibiotics10030272>
5. **Pontarelli A, Marchese V, Scolari C,** et al. Screening for active and latent tuberculosis among asylum seekers in Italy: A retrospective cohort analysis. *Travel Med Infect Dis.* 2019 Jan–Feb; 27: 39–45. DOI: <https://doi.org/10.1016/j.tmaid.2018.10.015>
6. **Villa S, Codecasa LR, Faccini M,** et al. Tuberculosis among asylum seekers in Milan, Italy: epidemiological analysis and evaluation of interventions. *Eur Respir J.* 2019 Oct 31; 54(4): 1900896. DOI: <https://doi.org/10.1183/13993003.00896-2019>
7. **Boudville DA, Joshi R, Rijkers GT.** Migration and tuberculosis in Europe. *J Clin Tuberc Other Mycobact Dis.* 2020 Jan 7; 18: 100143. DOI: <https://doi.org/10.1016/j.jctube.2020.100143>
8. **World Health Organization (WHO).** Consolidated guidelines on tuberculosis. Geneva: WHO; 7 July 2021. <https://www.who.int/publications/i/item/9789240029415>
9. **Palmieri F.** Per il Gruppo di Lavoro Tubercolosi-INMI “L. Spallanzani” Percorso Diagnostico Terapeutico Assistenziale Sulla Gestione del Paziente con Infezione/Malattia Tuberculare. Revisione N. 8/Gennaio 2020. Accessed 30 November 2021. [http://www.inmi.it/servizio/protocolli\\_e\\_linee\\_guida](http://www.inmi.it/servizio/protocolli_e_linee_guida).
10. **European Centre for Disease Prevention and Control & World Health Organization.** Regional Office for Europe. (2020). Tuberculosis surveillance and monitoring in Europe 2020: 2018 data. World Health Organization. Regional Office for Europe. <https://apps.who.int/iris/handle/10665/331530>.
11. **Kraef C, Bentzon A, Panteleev A,** et al. Delayed diagnosis of tuberculosis in persons living with HIV in Eastern Europe: associated factors and effect on mortality—a multicentre prospective cohort study. *BMC Infect Dis.* 2021 Oct 6; 21(1): 1038. DOI: <https://doi.org/10.1186/s12879-021-06745-w>
12. **Li J, Chung PH, Leung CLK, Nishikiori N, Chan EYY, Yeoh EK.** The strategic framework of tuberculosis control and prevention in the elderly: a scoping review towards End TB targets. *Infect Dis Poverty.* 2017 Jun 1; 6(1): 70. DOI: <https://doi.org/10.1186/s40249-017-0284-4>
13. **Di Gennaro F, Vitozzi P, Gualano G,** et al. Active Pulmonary Tuberculosis in Elderly Patients: A 2016–2019 Retrospective Analysis from an Italian Referral Hospital. *Antibiotics (Basel).* 2020 Aug 7; 9(8): 489. DOI: <https://doi.org/10.3390/antibiotics9080489>
14. **Kristensen KL, Ravn P, Petersen JH,** et al. Long-term risk of tuberculosis among migrants according to migrant status: a cohort study. *Int J Epidemiol.* 2020 Jun 1; 49(3): 776–785. DOI: <https://doi.org/10.1093/ije/dyaa063>
15. **Yen YF, Feng JY, Pan SW, Chuang PH, Su VY, Su WJ.** Determinants of mortality in elderly patients with tuberculosis: a population-based follow-up study. *Epidemiol Infect.* 2017 May; 145(7): 1374–1381. DOI: <https://doi.org/10.1017/S0950268817000152>
16. **Piergallini TJ, Turner J.** Tuberculosis in the elderly: Why inflammation matters. *Exp Gerontol.* 2018 May; 105: 32–39. DOI: <https://doi.org/10.1016/j.exger.2017.12.021>
17. **Ingrosso L, Vescio F, Giuliani M,** et al. Risk factors for tuberculosis in foreign-born people (FBP) in Italy: a systematic review and meta-analysis. *PLoS One.* 2014 Apr 14; 9(4): e94728. PMID: 24733156; PMCID: PMC3986251. DOI: <https://doi.org/10.1371/journal.pone.0094728>
18. **Chemtob D, Ogum E.** Tuberculosis treatment outcomes of non-citizen migrants: Israel compared to other high-income countries. *Isr J Health Policy Res.* 2020 Aug 3; 9(1): 29. PMID: 32741367; PMCID: PMC7397670. DOI: <https://doi.org/10.1186/s13584-020-00386-1>
19. **Di Gennaro F, Pizzol D, Cebola B,** et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review. *Tuberculosis (Edinb).* 2017 Mar; 103: 44–51. DOI: <https://doi.org/10.1016/j.tube.2017.01.002>
20. **Hargreaves S, Lönnroth K, Nellums LB,** et al. Multidrug-resistant tuberculosis and migration to Europe. *Clin Microbiol Infect.* 2017 Mar; 23(3): 141–146. DOI: <https://doi.org/10.1016/j.cmi.2016.09.009>

21. **Odono A, Riccò M, Morandi M, Borriani BM, Pasquarella C, Signorelli C.** Epidemiology of tuberculosis in a low-incidence Italian region with high immigration rates: differences between not Italy-born and Italy-born TB cases. *BMC Public Health*. 2011 May 23; 11: 376. DOI: <https://doi.org/10.1186/1471-2458-11-376>
22. **Di Gennaro F, Lattanzio R, Falanga C, et al.** Low-Wage Agricultural Migrant Workers in Apulian Ghettos, Italy: General Health Conditions Assessment and HIV Screening. *Trop Med Infect Dis*. 2021 Oct 15; 6(4): 184. DOI: <https://doi.org/10.3390/tropicalmed6040184>
23. **Merid MW, Gezie LD, Kassa GM, Muluneh AG, Akalu TY, Yenit MK.** Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: A retrospective cohort study. *BMC Infect Dis*. 2019; 19: 286. DOI: <https://doi.org/10.1186/s12879-019-3919-1>
24. **Lan Z, Ahmad N, Baghaei P, et al.** Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. *Lancet Respir Med*. 2020 Apr; 8(4): 383–394. DOI: [https://doi.org/10.1016/S2213-2600\(20\)30047-3](https://doi.org/10.1016/S2213-2600(20)30047-3)
25. **Noor S, Ismail M, Khan F.** Drug safety in hospitalized patients with tuberculosis: Drug interactions and adverse drug effects. *Clin Respir J*. 2021 Jan; 15(1): 97–108. DOI: <https://doi.org/10.1111/crj.13276>
26. **Borisov S, Danila E, Maryandyshev A, et al.** Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report. *Eur Respir J*. 2019 Dec 19; 54(6): 1901522. DOI: <https://doi.org/10.1183/13993003.01522-2019>
27. **Holden IK, Andersen PH, Wejse C, Lillebaek T, Johansen IS.** Review of tuberculosis treatment outcome reporting system in Denmark, a retrospective study cohort study from 2009 through 2014. *BMC Health Serv Res*. 2020 Feb 3; 20(1): 83. PMID: 32013962; PMCID: PMC6998178. DOI: <https://doi.org/10.1186/s12913-020-4927-y>
28. **Peri AM, Bernasconi DP, Galizzi N, et al.** Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. *BMC Infect Dis*. 2018 Dec 20; 18(1): 690. DOI: <https://doi.org/10.1186/s12879-018-3609-4>
29. **Pezzotti P, Pozzato S, Ferroni E, et al.** Delay in diagnosis of pulmonary tuberculosis: A survey in the Lazio region, Italy *Epidemiology Biostatistics and Public Health*. 2015; 1–10: 12.
30. **Koo HK, Min J, Kim HW, et al.** Prediction of treatment failure and compliance in patients with tuberculosis. *BMC Infect Dis*. 2020 Aug 24; 20(1): 622. DOI: <https://doi.org/10.1186/s12879-020-05350-7>
31. **Riccardi N, Pontarelli A, Alagna R, et al.** Epidemiology and treatment outcome of MDR and pre-XDR TB in international migrants at two reference centers in the North of Italy: a cross-sectional study coordinated by Stop TB Italia Onlus. *Public Health*. 2020 Mar; 180: 17–21. DOI: <https://doi.org/10.1016/j.puhe.2019.10.022>
32. **Aslam MV, Owusu-Edusei K, Marks SM, et al.** Number and cost of hospitalizations with principal and secondary diagnoses of tuberculosis, United States. *Int J Tuberc Lung Dis*. 2018; 22(12): 1495–1504. DOI: <https://doi.org/10.5588/ijtld.18.0260>
33. **Nishikiori N, Van Weezenbeek C.** Target prioritization and strategy selection for active case-finding of pulmonary tuberculosis: a tool to support country-level project planning. *BMC Public Health*. 2013; 13: 97. DOI: <https://doi.org/10.1186/1471-2458-13-97>
34. **World Health Organization (WHO).** *Implementing the end TB Strategy*. Geneva 2015. <https://www.who.int/publications/i/item/implementing-the-end-tb-strategy>.
35. **Saunders MJ, Evans CA.** COVID-19, tuberculosis and poverty: preventing a perfect storm. *Eur Respir J*. 2020 Jul 9; 56(1): 2001348. DOI: <https://doi.org/10.1183/13993003.01348-2020>
36. **Di Gennaro F, Marotta C, Antunes M, Pizzol D.** Diabetes in active tuberculosis in low-income countries: to test or to take care? *Lancet Glob Health*. 2019 Jun; 7(6): e707. DOI: [https://doi.org/10.1016/S2214-109X\(19\)30173-1](https://doi.org/10.1016/S2214-109X(19)30173-1)

#### TO CITE THIS ARTICLE:

Di Gennaro F, Lattanzio R, Guido G, Ricciardi A, Novara R, Patti G, Cotugno S, De Vita E, Brindicci G, Mariano MF, Ronga L, Santoro CR, Romanelli F, Stolfà S, Papagni R, Bavaro DF, De Iaco G, Saracino A. Predictors for Pulmonary Tuberculosis Outcome and Adverse Events in an Italian Referral Hospital: A Nine-Year Retrospective Study (2013–2021). *Annals of Global Health*. 2022; 88(1): 26, 1–12. DOI: <https://doi.org/10.5334/aogh.3677>

Published: 26 April 2022

#### COPYRIGHT:

© 2022 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See <http://creativecommons.org/licenses/by/4.0/>.

*Annals of Global Health* is a peer-reviewed open access journal published by Ubiquity Press.

